Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00221182
Other study ID # BRI CAD 04-01
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received September 13, 2005
Last updated June 21, 2011
Start date September 2005
Est. completion date September 2009

Study information

Verified date June 2011
Source Foundation for Biomedical Research and Innovation
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if stem cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will relieve your chest pain, increase the blood flow, and/or improve the cardiac contractility (function) by regenerating blood vessels in your heart.


Description:

Chronic myocardial ischemia (MI) is a progressive disease, which arises as a result of atherosclerosis in coronary arteries. Prognosis of chronic MI is poor, and no effective treatments have been established in patients who are not eligible for the traditional revascularization therapies such as angioplasty and bypass procedures due to the inappropriate anatomy of the coronary arteries or frequent reocclusion following revascularization. Therefore, it is necessary to establish novel revascularization treatment to improve prognosis of the no-option patients. We will study the safety and clinical efficiency of vascular regeneration by means of transplantation of autologous peripheral blood endothelial progenitor cells (CD34 positive cells) in patients with severe chronic coronary artery disease (CAD) who are not eligible for traditional revascularization treatments. The primary endpoint is the severity of myocardial ischemia identified by sestamibi SPECT stress myocardial scintigraphy and the evaluation of adverse effect rates, while the secondary endpoints are evaluation of CCSAS and NYHA classification, regional myocardial blood flow as revealed by PET scan, and various left ventricular function indices.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date September 2009
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

-Chronic severe CAD patients fulfilling all the following criteria are considered suitable for inclusion in the study.

1. At least 6 months since last episode of myocardial infarction or at least 3 months since initial anginal episode.

2. Patients fulfilling either of the following criteria based on the extent of CAD by coronary angiography and LVEF by echocardiography.

- Patients with single vessel CAD and LVEF < 50%

- Patients with multivessel CAD

3. Reversible myocardial ischemia as revealed by sestamibi SPECT stress myocardial scintigraphy.

4. Patients for whom angioplasty and bypass are not indicated because of anatomical or procedural reasons or frequent reocclusion/restenosis following traditional revascularization.

5. Age is between 20 and 80 (at time of consent).

6. Exercise tolerance time (ETT) duration = 3 minutes and < 13 minutes on a modified Bruce protocol on 2 consecutive tests (> 24 hours but < 2 weeks apart), with the difference between the 2 exercise times within 25% of their mean (Patients should not be informed of exercise restrictions required for entry into the study).

7. Patients who can give informed consent themselves in writing.

Exclusion Criteria:

- Any one of the following exclusion criteria is sufficient to disqualify a patient from the study.

1. Sustained ventricular tachycardia in a 24-hour ECG.

2. Chronic atrial fibrillation.

3. Less than 6 months since last episode of cerebral infarction.

4. Less than 6 months since last coronary angioplasty or less than 3 months since last bypass surgery.

5. Patients with unstable angina, with a treatment rating of 3 in the Braunwald system (refer to 5.4.), but a severity of III and a clinical rating of B or C.

6. Presence of left ventricular thrombus by echocardiography

7. Patients with a malignant tumor*.

8. Patients with diabetic proliferating retinopathy** (new Fukuda classification BI to BV).

9. Patients with chronic rheumatoid arthritis.

10. Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis.

11. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).

12. Patients currently suffering from or having a history of interstitial pneumonitis.

13. Patients for whom cranial MRA reveals cerebral aneurysm.

14. Patients for whom abdominal CT or ultrasonography reveals splenomegaly.

15. Patients with cirrhosis of the liver.

16. Patients who cannot discontinue Warfarin.

17. Leukocytes less than 4,000/µL or exceeding 10,000/µL.

18. Platelets less than 100,000/µL.

19. Hemoglobin less than 10 g/dL.

20. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.

21. Patients for whom it is impossible to perform both cardiac MRI and left ventriculography (LVG) (see 9.2.4 for cardiac MRI details and 9.2.9 for LVG details).

22. Patients with gate disturbance for reasons other than CAD (such as critical limb ischemia, sciatic neuralgia, or vasculitis), making exercise tolerance evaluation on a treadmill with stress ECG difficult.

23. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.

24. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Genetic:
Autologous peripheral blood CD34 positive cell therapy


Locations

Country Name City State
Japan Kobe City General Hospital Kobe Hyogo
Japan Kobe Institute of Biomedical Research and Innovation Kobe Hyogo-Pref.
Japan Okayama University School of Medicine Okayama

Sponsors (4)

Lead Sponsor Collaborator
Foundation for Biomedical Research and Innovation Institute of Biomedical Research and Innovation, Kobe,Hyogo, Japan, Kobe City General Hospital, Okayama University School of Medicine

Country where clinical trial is conducted

Japan, 

References & Publications (6)

Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol. 2004 Sep;287(3):C572-9. Review. — View Citation

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997 Feb 14;275(5302):964-7. — View Citation

Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3422-7. — View Citation

Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001 Feb 6;103(5):634-7. — View Citation

Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, Uchida S, Masuo O, Iwaguro H, Ma H, Hanley A, Silver M, Kearney M, Losordo DW, Isner JM, Asahara T. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation. 2003 Jan 28;107(3):461-8. — View Citation

Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999 Apr;5(4):434-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy: Severity of myocardial perfusion abnormality by sestamibi SPECT stress myocardial scintigraphy
Primary Safety: Severe adverse events within 4 weeks after cell therapy
Secondary CCSAS (Canada Cardiovascular Society Anginal Score)
Secondary NYHA (New York Heart Association) classification
Secondary Exercise tolerance by treadmill
Secondary Left ventricular function by cardiac MRI
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A